Tinea Versicolor Treatment Market Analysis

Tinea Versicolor Treatment Market Overview

The Tinea Versicolor Treatment Market is projected to reach USD 374.6 Million by 2030 at 9.2% CAGR during the forecast period 2022-2030. Tinea Versicolor is one of the common types of skin infection. It also called as pityriasis versicolor. In this condition, small and discolored patches of skin occur, mostly affecting the shoulders and trunk.

Increasing prevalence of tinea versicolor, increasing awareness of the disease, rising healthcare expenditure, advanced diagnosis and treatment options, and approval of new antifungal medicines are leading the growth of tinea versicolor treatment market.

In May 2023, Astellas Pharma, the leading provider of therapies for tinea versicolor in Japan, has agreed to purchase Iveric Bio Inc., a US-based pharmaceutical company, for an estimated amount of $5.9 billion. Astellas Pharma will have access to a diverse range of ophthalmology medications with this transaction. Astellas, the third largest pharmaceutical company in Japan in terms of revenue, has successfully concluded its fifth major international purchase since 2019 with the aim of fortifying its pipeline as the patent protection for its main products nears expiration. Refinitiv data reveals that this deal is the second-biggest cross-border purchase made by a Japanese pharmaceutical company in the past five years. The greatest acquisition during this period was Takeda Pharmaceutical Co.'s $6 billion purchase of Nimbus Therapeutics' psoriasis medicine unit, which was revealed in December. 

In November 2023, Bayer and Recursion Pharmaceuticals declared their decision to redirect their collaboration towards oncology. This shift entails a change in their focus from net sales royalties and milestone payments to the advancement of up to seven oncology studies. Recursion stands to receive a maximum of $1.5 billion in potential compensation. Recursion has recently announced a $160 million, five-year arrangement with Tempus, granting them exclusive access to more than 20 petabytes of data. The data provided consists of oncology datasets that are focused on patients. These datasets have been de-identified and include patient health records, as well as DNA and RNA information. Furthermore, Recursion announced its plan to increase the computational power of its BioHive-1 supercomputer by fourfold. This will be achieved by procuring more than 500 NVIDIA H100 Tensor Core GPUs, in addition to the existing 300 A100 Tensor Core GPUs that are now in use. The purpose of this expansion was to facilitate and enhance this partnership as well as other similar endeavors.

Study objectives of tinea versicolor treatment market:

• To provide detailed analysis of the tinea versicolor treatment market structure with historical and forecast revenue for the next six years of the various segments and sub-segments.


• To provide insights about the key drivers, restraints, opportunities and challenges affecting the growth of tinea versicolor treatment market


• To provide analysis of the market with respect to various countries in the four main geographies– the Americas, Europe, Asia Pacific, and Middle East & Africa.


• To provide detailed analysis of the market segmented by diagnosis, treatment, end user, and its sub-segments.


• To provide a detailed analysis of tinea versicolor treatment market mainly based on Value Chain Analysis, Porter’s Five Forces, Price Analysis, and Supply Chain Analysis etc.


• To provide a detailed country level analysis of the market with respect to the current market size and future prospects


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the tinea versicolor treatment market


• To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the tinea versicolor treatment market

FIGURE 1  TINEA VERSICOLOR TREATMENT MARKET SHARE BY END USER, 2016 (%)

Sources: DermNet New Zealand Trust, National Center for Biotechnology Information (NCBI), American Academy of Dermatology, U.S. National Library of Medicine, Directorate of Industries, Annual report, White paper, Company Presentation

Intended Audience:

• Tinea versicolor medicines manufacturers


• Tinea versicolor medicines and treatment providers


• Medical research laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Potential Investors

Research Methodology:

Sources: DermNet New Zealand Trust, National Center for Biotechnology Information (NCBI), American Academy of Dermatology, U.S. National Library of Medicine, Directorate of Industries, Annual report, White paper, Company Presentation.

Tinea Versicolor Treatment Market Segmentation     

Tinea versicolor treatment market has been segmented on the basis of diagnosis which comprise physical exam, imaging tests, and others. Imaging test is sub-segmented into wood lamp (black light) examination, microscopy using potassium hydroxide (KOH), fungal culture, skin biopsy, and others. Skin biopsy is sub-segmented into shave biopsy, punch biopsy, excisional biopsy, and others.

On the basis of treatments, the market has been segmented into antifungal shampoos, antifungal creams, drugs, and others. Antifungal shampoos are sub-segmented into selenium sulfide (selsun) 2.5 percent shampoo, ciclopirox (loprox, penlac) shampoo, ketoconazole (ketoconazole, nizoral, others) shampoo, and others. Antifungal creams are sub-segmented into Selenium sulfide (Selsun) 2.5 percent lotion, Ciclopirox (Loprox, Penlac) cream or gel, Ketoconazole (Ketoconazole, Nizoral, others) cream or gel, and others. Drugs are further sub-segmented into fluconazole (diflucan) tablets or oral solution, and others.

On the basis of end user, it is segmented into dermatology hospital and clinics, medical research centers, academic institutes, and others.

Regional Analysis of Tinea Versicolor Treatment Market

Considering the global scenario of the market, America is the top contributor in this market. The Americas mainly include North America and South America. Due to large amount of money invested in research, clinical trials, and new product development, US is the dominating country in this region. Europe is the second largest market for tinea versicolor treatment. Germany is dominating this market while UK is the fastest growing tinea versicolor treatment market. Asia Pacific is witnessing rapid growth in this market which is mainly due to rapidly improving healthcare facilities, increasing awareness of disease, and rising healthcare expenditure. Middle East & Africa is expected to have limited growth.

Key Players for Tinea Versicolor Treatment Market      

Some of the key players in this tinea versicolor treatment market are: 

• Astellas Pharma US, Inc. (Japan) 


• Bayer AG (German)


• Enzon Pharmaceuticals, Inc. (US)


• Galderma S.A. (Switzerland) 


• Gilead (US) 


• Novartis AG (Switzerland) 


• Pfizer Inc. (US) 


• Taro Pharmaceutical Industries Ltd. (US) 


• Teva Pharmaceutical Industries Ltd. (Israel) 


• Valeant (Canada)

The report for Global Tinea Versicolor Treatment Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions